Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF -mutant metastatic melanoma: a real-world propensity score–matched survival analysis.
Saved in:
| Title: | Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF -mutant metastatic melanoma: a real-world propensity score–matched survival analysis. |
|---|---|
| Authors: | Garitaonaindia, Yago1 (AUTHOR), Khan, Shawez1 (AUTHOR), Friis, Rasmus2 (AUTHOR), Kjær, Søren3 (AUTHOR), Borch, Troels H1 (AUTHOR), Ruhlmann, Christina3 (AUTHOR), Guldbrandt, Louise M2 (AUTHOR), Luczak, Adam A4 (AUTHOR), Schmidt, Henrik2 (AUTHOR), Bastholt, Lars3 (AUTHOR) |
| Source: | JNCI: Journal of the National Cancer Institute. Feb2026, Vol. 118 Issue 2, p261-268. 8p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
